Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.681
https://www.valueinhealthjournal.com/article/S1098-3015(13)02586-2/fulltext
Title :
Sources of Long-Term Quality Adjusted Life Year (QALY) Gains for Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02586-2&doi=10.1016/j.jval.2013.08.681
First page :
A441
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
655